07 Mar Syncrosome and the Microbiome… Follow us at Pharmabiotics2018
Syncrosome invites you to visit us at Pharmabiotics2018, March 14th to November 15th 2018, in Paris, France.
Emmanuelle Bettendorf, our Business Developer would be delighted to meet you their and discuss your in vivo preclinical projects.
We can give you advice about our in vivo Gastrointestinal efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that you might have or just to get to know each other.
A few words about Syncrosome:
Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.
We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.
Our main activities consit in :
- Drug Efficacy Studies in several therapeutic areas :
- Central Nervous Sytem,
- Cardiovascular and Metabolic disease,
- Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.